Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Accounts Payables (2019 - 2025)

Historic Accounts Payables for IDEAYA Biosciences (IDYA) over the last 7 years, with Q3 2025 value amounting to $18.4 million.

  • IDEAYA Biosciences' Accounts Payables rose 4667.78% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 million, marking a year-over-year increase of 4667.78%. This contributed to the annual value of $15.4 million for FY2024, which is 13372.23% up from last year.
  • According to the latest figures from Q3 2025, IDEAYA Biosciences' Accounts Payables is $18.4 million, which was up 4667.78% from $17.3 million recorded in Q2 2025.
  • IDEAYA Biosciences' 5-year Accounts Payables high stood at $18.4 million for Q3 2025, and its period low was $1.3 million during Q1 2021.
  • For the 5-year period, IDEAYA Biosciences' Accounts Payables averaged around $7.8 million, with its median value being $5.2 million (2023).
  • Examining YoY changes over the last 5 years, IDEAYA Biosciences' Accounts Payables showed a top increase of 18030.21% in 2025 and a maximum decrease of 871.21% in 2025.
  • IDEAYA Biosciences' Accounts Payables (Quarter) stood at $2.1 million in 2021, then skyrocketed by 103.81% to $4.3 million in 2022, then soared by 54.16% to $6.6 million in 2023, then soared by 133.72% to $15.4 million in 2024, then increased by 19.53% to $18.4 million in 2025.
  • Its Accounts Payables stands at $18.4 million for Q3 2025, versus $17.3 million for Q2 2025 and $17.6 million for Q1 2025.